GELNIQUE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for GELNIQUE (GELNIQUE).

How it works

GELNIQUE (oxybutynin) is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), primarily M3 receptors in the detrusor muscle of the bladder, reducing bladder contractions and increasing bladder capacity.

What the body does with it

Metabolism	Extensively metabolized by cytochrome P450 enzymes, primarily CYP3A4, to active and inactive metabolites; undergoes first-pass metabolism.
Excretion	Approximately 75% of the dose is excreted renally as unchanged drug and metabolites (primarily N-desethyloxybutynin), with about 25% excreted in feces via biliary elimination.
Half-life	Terminal elimination half-life is approximately 12-13 hours for oxybutynin and 8-10 hours for the active metabolite N-desethyloxybutynin, allowing for once-weekly transdermal dosing.
Protein binding	Oxybutynin is approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	The apparent volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
Bioavailability	Transdermal: approximately 100% bioavailability relative to IV, with steady-state concentrations achieved by day 3-4.
Onset of Action	Transdermal: Clinical effect is observed within 24-48 hours after application, with steady-state concentrations achieved by day 3-4.
Duration of Action	Each application provides continuous delivery for 7 days, with sustained plasma concentrations over the wear period. Clinical effect persists for the full week of wear.

Classification & Brands

Dosing & administration

Apply 1 gram (1 sachet) of gel once daily to clean, dry, intact skin on the abdomen, upper arms, shoulders, or thighs. Each gram contains 100 mg oxybutynin.

Dosage form	GEL
Renal impairment	No specific dose adjustment for GFR; use caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation.
Liver impairment	Contraindicated in Child-Pugh Class C cirrhosis; no specific recommendations for Class A or B, but use with caution due to increased systemic exposure.
Pediatric use	Not approved for pediatric patients (safety and efficacy not established).
Geriatric use	Start at the lowest effective dose (1 gram daily) due to increased risk of anticholinergic side effects (e.g., cognitive impairment, falls). Monitor renal function as elderly often have reduced GFR.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for GELNIQUE (GELNIQUE).

Breastfeeding	Oxybutynin is excreted into breast milk but in low concentrations; M/P ratio not established. Caution in nursing mothers. Consider alternative agents with more safety data.
Teratogenic Risk	Pregnancy Category B. No evidence of fetal harm in animal studies. No adequate well-controlled studies in pregnant women. Use only if clearly needed. First trimester: theoretical risk based on anticholinergic effects; avoid unless necessary. Second/third trimester: increased risk of preterm labor due to oxybutynin's tocolytic properties? No direct teratogenicity reported.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Urinary retention","Gastric retention","Uncontrolled narrow-angle glaucoma","Hypersensitivity to oxybutynin or any component of the formulation"]

Clinical Precautions

Precautions

["May cause angioedema requiring immediate treatment","Exacerbation of symptoms in patients with myasthenia gravis","Decreased gastrointestinal motility in patients with ulcerative colitis or intestinal atony","Heat prostration in hot environments due to decreased sweating","Central nervous system effects including dizziness, somnolence, and confusion","Caution in patients with impaired renal or hepatic function","May worsen urinary retention, gastric retention, uncontrolled narrow-angle glaucoma"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

GELNIQUE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for GELNIQUE (GELNIQUE).

How it works

What the body does with it

Metabolism	Extensively metabolized by cytochrome P450 enzymes, primarily CYP3A4, to active and inactive metabolites; undergoes first-pass metabolism.
Excretion	Approximately 75% of the dose is excreted renally as unchanged drug and metabolites (primarily N-desethyloxybutynin), with about 25% excreted in feces via biliary elimination.
Half-life	Terminal elimination half-life is approximately 12-13 hours for oxybutynin and 8-10 hours for the active metabolite N-desethyloxybutynin, allowing for once-weekly transdermal dosing.
Protein binding	Oxybutynin is approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	The apparent volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
Bioavailability	Transdermal: approximately 100% bioavailability relative to IV, with steady-state concentrations achieved by day 3-4.
Onset of Action	Transdermal: Clinical effect is observed within 24-48 hours after application, with steady-state concentrations achieved by day 3-4.
Duration of Action	Each application provides continuous delivery for 7 days, with sustained plasma concentrations over the wear period. Clinical effect persists for the full week of wear.

Classification & Brands

Dosing & administration

Apply 1 gram (1 sachet) of gel once daily to clean, dry, intact skin on the abdomen, upper arms, shoulders, or thighs. Each gram contains 100 mg oxybutynin.

Dosage form	GEL
Renal impairment	No specific dose adjustment for GFR; use caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation.
Liver impairment	Contraindicated in Child-Pugh Class C cirrhosis; no specific recommendations for Class A or B, but use with caution due to increased systemic exposure.
Pediatric use	Not approved for pediatric patients (safety and efficacy not established).
Geriatric use	Start at the lowest effective dose (1 gram daily) due to increased risk of anticholinergic side effects (e.g., cognitive impairment, falls). Monitor renal function as elderly often have reduced GFR.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for GELNIQUE (GELNIQUE).

Breastfeeding	Oxybutynin is excreted into breast milk but in low concentrations; M/P ratio not established. Caution in nursing mothers. Consider alternative agents with more safety data.
Teratogenic Risk	Pregnancy Category B. No evidence of fetal harm in animal studies. No adequate well-controlled studies in pregnant women. Use only if clearly needed. First trimester: theoretical risk based on anticholinergic effects; avoid unless necessary. Second/third trimester: increased risk of preterm labor due to oxybutynin's tocolytic properties? No direct teratogenicity reported.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Urinary retention","Gastric retention","Uncontrolled narrow-angle glaucoma","Hypersensitivity to oxybutynin or any component of the formulation"]